However, in a recent analysis of 177 Proseek proteins (from the Oncology II and Inflammation panels) used to distinguish benign tumors from borderline tumors and ovarian cancer, ITGAV was the only individual biomarker found to improve the performance of the reference model (CA125, HE4 and age) [39]. This evidence concerns the gene MUC16 and benign neoplasm.